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A B S T R A C T 15 
Only a few drugs are available for treating sleeping sickness and nagana disease; 16 
parasitic infections caused by protozoans of the genus Trypanosoma in sub-Saharan 17 
Africa. There is an urgent need for the development of new medicines for 18 
chemotherapy of these devastating diseases. In this study, three newly designed 19 
thiosemicarbazone iron chelators, TSC24, Dp44mT and 3-AP, were tested for in vitro 20 
activity against bloodstream forms of T. brucei and human leukaemia HL-60 cells. In 21 
addition to their iron chelating properties, TSC24 and Dp44mT inhibit topoisomerase 22 
IIα while 3-AP inactivates ribonucleotide reductase. All three compounds exhibited 23 
anti-trypanosomal activity, with minimum inhibitory concentration (MIC) values 24 
ranging between 1 and 100 μM and 50% growth inhibition (GI50) values of around 25 
250 nM. Although the compounds did not kill HL-60 cells (MIC values >100 μM), 26 
TSC24 and Dp44mT displayed considerable cytotoxicity based on their GI50 values. 27 
Iron supplementation partly reversed the trypanotoxic and cytotoxic activity of TSC24 28 
and Dp44mT but not of 3-AP. This finding suggests possible synergy between the 29 
iron chelating and topoisomerase IIα inhibiting activity of the compounds. However, 30 
further investigation using separate agents, the iron chelator deferoxamine and the 31 
topoisomerase II inhibitor epirubicin, did not support any synergy for the interaction 32 
of iron chelation and topoisomerase II inhibition. Furthermore, TSC24 was shown to 33 
induce DNA degradation in bloodstream forms of T. brucei indicating that the 34 
mechanism of trypanotoxic activity of the compound is topoisomerase II independent. 35 
In conclusion, the data support further investigation of thiosemicarbazone iron 36 
chelators with dual activity as lead compounds for anti-trypanosomal drug 37 
development. 38 
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1. Introduction 45 
 46 
African trypanosomes are the etiological agents of sleeping sickness in humans 47 
and nagana disease in cattle (Steverding, 2008). The parasites are transmitted by the 48 
bite of infected tsetse flies (Glossina spp.) and live and multiply in the blood and 49 
tissue fluids of their mammalian host. Trypanosomiasis affects both humans and 50 
animals mainly in rural sub-Saharan Africa where the disease imposes significant 51 
burden on public health and economic development. Without treatment, both sleeping 52 
sickness and nagana disease are fatal. Sadly, few drugs are available for 53 
chemotherapy of African trypanosomiasis (Holmes et al. 2004; Steverding, 2010). In 54 
addition, most drugs are outdated and difficult to administer. Moreover, drug 55 
resistance in African trypanosomes is an increasing problem in the therapy of both 56 
sleeping sickness and nagana disease (Matovu et al., 2001; Delespaux and de Koning, 57 
2007). Thus, new strategies are needed if novel chemotherapies are to be developed. 58 
One strategy to improve the activity of drugs is the conjugation of two bioactive 59 
moieties. For instance, the conjugate of the iron chelator deferiprone and a 60 
chloroquine fragment (7-chloro-4-aminoquinoline) has been shown to display higher 61 
trypanotoxic activity than both parent compounds alone (Gehrke et al., 2013). Other 62 
examples of compounds with dual activity are thiosemicarbazones. For instance, the 63 
compounds Dp44mT and TSC24 (Fig. 1) possess both iron chelating and 64 
topoisomerase IIα inhibiting activity (Rao et al., 2009; Huang et al., 2010) while the 65 
compound 3-AP (Fig. 1) exhibits iron chelating and ribonucleotide reductase 66 
inhibiting activity (Finch et al., 1999; Aye et al., 2012). As topoisomerases and 67 
ribonucleotide reductase are essential enzymes involved in the metabolism and 68 
replication of DNA (Corbett and Berger, 2004; Nordlund and Reichard, 2006), and as 69 
iron chelation has been shown to limit the proliferation of bloodstream form 70 
trypanosomes (Breidbach et al., 2002; Merschjohann and Steverding, 2006), 71 
inhibition of these enzymes in combination with iron depletion may be an interesting 72 
option for the development of novel anti-trypanosomal chemotherapies. For this 73 
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reason, we studied the in vitro trypanotoxic activity of the thiosemicarbazones TSC24, 74 
Dp44mT and 3-AP using bloodstream forms of Trypanosoma brucei. In addition, we 75 
investigated whether the combination of iron chelation and topoisomerase inhibition 76 
shows synergy. 77 
 78 
2. Materials and methods 79 
 80 
2.1. Reagents 81 
 82 
Deferoxamine mesylate, di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone 83 
(Dp44mT), 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and 84 
ammonium ferric citrate were purchased from Sigma-Aldrich (Gillingham, U.K.). (E)-85 
N,N-dimethyl-2-(quinolin-2-ylmethylene)hydrazinecarbothioamide (TSC24) was 86 
from Merck Chemicals Ltd. (Nottingham, U.K.). Epirubicin hydrochloride was 87 
obtained from Cambridge Bioscience Ltd. (Cambridge, U.K.). 88 
 89 
2.2. Cell cultures 90 
 91 
Bloodstream forms of T. brucei clone 427-221a (Hirumi et al., 1980) and human 92 
myeloid leukaemia HL-60 cells (Collins et al., 1977) were grown in Baltz medium 93 
(Baltz et al., 1985) and RPMI medium (Moore et al., 1967), respectively. Both media 94 
were supplemented with 16.7% (v/v) heat-inactivated foetal calf serum. All cultures 95 
were maintained in a humidified atmosphere containing 5% CO2 at 37°C. 96 
 97 
2.3. Toxicity assays 98 
 99 
Trypanosomes and HL-60 cells were seeded in 24-well plates in a final volume of 100 
1 ml culture medium containing various concentrations of thiosemicarbazones 101 
dissolved in 100% DMSO. Controls contained DMSO alone. In all experiments, the 102 
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final DMSO concentration was 1%. The seeding densities were 10
4
/ml trypanosomes 103 
and 10
5
/ml HL-60 cells. For toxicity assays including iron supplementation, 10 μl of 104 
medium was replaced with 10 μl of a 1.93 mg/ml ammonium ferric citrate solution to 105 
give a final iron(III) concentration of 50 μM. After 48 h of incubation, living cells 106 
were counted with a Neubauer haemocytometer. The 50% growth inhibition (GI50) 107 
values, i.e. the concentration of compounds necessary to reduce the growth rate of 108 
cells by 50% to that of controls, was determined by linear interpolation according to 109 
the method described in (Huber and Koella, 1993). The minimum inhibitory 110 
concentration (MIC) values, i.e. the concentration of the compounds at which all cells 111 
were killed, was determined microscopically. 112 
 113 
2.4. Flow cytometric analysis 114 
 115 
Flow cytometric analysis was performed as described previously (Phillips et al., 116 
2013). Bloodstream form trypanosomes (1-5 × 10
6
/ml) were incubated with 500 nM 117 
TSC24, 50 μM ammonium ferric citrate, 5 μM TSC plus 50 μM ammonium ferric 118 
citrate or 1% DMSO for 24 h. After harvesting by centrifugation at 850×g and 119 
washing twice with PBS/1% glucose, cells were fixed in 100 μl ice-cold methanol for 120 
5 min and then diluted with 1 ml PBS. After centrifugation, the cell pellets were re-121 
suspended in PBS and stained with propidium iodide (final concentration 50 µg/ml). 122 
Cells were analysed on a BD Accuri C6 Flow Cytometer. Debris was excluded from 123 
analysis through gating on forward scatter and side scatter properties. Singlets were 124 
identified and doublets excluded through gating on FL-2 (585/40 nm) area versus 125 
height. A minimum of 10,000 cells were collected for analysis. Data was analysed 126 
using FlowJo version 10.  127 
 128 
2.5. Isobolographic analysis 129 
 130 
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The interaction of the iron chelator deferoxamine and the topoisomerase II 131 
inhibitor epirubicin was evaluated using the isobolographic method as described 132 
previously (Steverding and Wang, 2009). First, the GI50 value for each drug was 133 
determined. Based on the GI50 values, bloodstream form trypanosomes were 134 
incubated with twofold serially diluted 1:1 ratios of drug combination. For controls, 135 
trypanosomes were cultured with twofold serially diluted concentrations of each drug 136 
alone. After 48 h incubation, live cells were counted and the GI50 value for each drug 137 
in the absence and in the presence of the other co-administered drug was determined. 138 
The combination index (CI) for the drug combination was calculated using the 139 
equation 140 
 141 
 GI50(DFO,com) GI50(EPI,com) 142 
CI = —————— + —————— 143 
 GI50(DFO,sin) GI50(EPI,sin) 144 
 145 
where GI50(DFO,com) and GI50(EPI,com) are the concentrations of deferoxamine and 146 
epirubicin used in the combination to achieve 50% growth inhibition and GI50(DFO,sin) 147 
and GI50(EPI,sin) are the concentrations of deferoxamine and epirubicin alone to achieve 148 
the same effect. A CI value of <1, =1, and >1 indicates synergism, additive effect, and 149 
antagonism, respectively.
6
 150 
 151 
3. Results 152 
 153 
The trypanotoxic activity of the thiosemicarbazones TSC24, Dp44mT and 3-AP 154 
was determined with bloodstream forms of the T. brucei strain 427-221a while the 155 
general cytotoxicity of the compounds was evaluated with human myeloid leukaemia 156 
HL-60 cells. All three thiosemicarbazones showed a dose-dependent effect on the 157 
inhibition of the growth of trypanosomes in cell culture with similar GI50 values 158 
ranging between 0.226 and 0.287 μM (Table 1). Statistical analysis revealed no 159 
significant difference between the GI50 values of the three compounds (ANOVA, p = 160 
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0.574). Both TSC24 and Dp44mT displayed a promising MIC value of 1 μM while 3-161 
AP a less favourable value of 100 μM (Table 1) demonstrating that all three 162 
compounds are trypanocidal. By comparison, clinically used anti-sleeping sickness 163 
drugs display much higher anti-trypanosomal activities. For example, pentamidine, 164 
melarsoprol and surmamin exhibit GI50 values of 0.001 μM, 0.016 μM and 0.032 μM, 165 
and MIC values of 0.006 μM, 0.1 μM and 1 μM, respectively (Merschjohann et al., 166 
2001; Caffrey et al., 2007; Steverding et al., 2014). The thiosemicarbazones also 167 
inhibited the proliferation of HL-60 cells but with GI50 values varying between 0.005 168 
and 0.673 μM (Table 1). Dp44mT and TSC24 proved to be more effective in 169 
inhibiting the growth of HL-60 cells than that of trypanosomes. However, all three 170 
compounds had a MIC value of >100 μM indicating that they were cytostatic rather 171 
than cytocidal. Anti-sleeping sickness drugs, on the other hand, are much less toxic to 172 
HL-60 cells. For example, the GI50 values of pentamidine, melarsoprol and suramin 173 
are 33 μM, 4 μM and >100 μM, respectively, while their MIC values are 100 μM 174 
(Merschjohann et al., 2001; Caffrey et al., 2007; Steverding et al., 2014). As a result, 175 
the GI50 and MIC ratios of cytotoxic to trypanotoxic activities (selectivity indices) for 176 
the thiosemicarbazones were much less favourable than those of anti-sleeping 177 
sickness drugs. TSC24 and Dp44mT had a GI50 ratio of <1 while their corresponding 178 
MIC ratio was, at >100, more promising (Table 2). The GI50 and MIC ratios for 3-AP 179 
were 2.85 and >1 indicating poor selectivity of this drug. In contrast, the GI50 and 180 
MIC ratios of anti-sleeping sickness drugs are much higher (pentamindine: 9,800 and 181 
13,000; melarsoprol: 267 and >1,000; suramin: >100 and >1,000) (Merschjohann et 182 
al., 2001; Caffrey et al., 2007; Steverding et al., 2014). 183 
Supplementation of iron partially reversed the trypanotoxic activity of TSC24 and 184 
Dp44mT causing a 13- and 100-fold increase of their GI50 and MIC values, 185 
respectively (Table 1). This finding supports the notion that both thiosemicarbazones 186 
could chelate iron in cells, which may have contributed to the trypanotoxic activity of 187 
the compounds. In contrast, addition of iron did not impair the anti-trypanosomal 188 
activity of 3-AP (Table 1). Iron supplementation also reduced the cytotoxicity of the 189 
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compounds (Table 1). However, the GI50 values for TSC24 and Dp44mT for HL-60 190 
cells increased only 5- and 7-fold, respectively, which was lower than those observed 191 
for the compounds for trypanosomes. As the addition of iron shifted the trypanotoxic 192 
and the cytotoxic activity of the compounds in the same direction, no change in the 193 
MIC and GI50 ratios were observed apart from a 100-fold drop in the MIC ratios for 194 
TSC24 and Dp44mT (Table 2). 195 
As TSC24 and Dp44mT are inhibitors of topoisomerase IIα and displayed almost 196 
equal trypanotoxic activities indicating that their mechanism of anti-trypanosomal 197 
action is identical, TSC24 was chosen to investigate the effect of this 198 
thiosemicarbazone on the cell cycle progression in T. brucei. Bloodstream form 199 
trypanosomes were incubated for 24 h in the absence or presence of iron with TSC24 200 
at concentrations sufficient to inhibit the growth of the cells without killing them. The 201 
iron supplementation control showed little change in the cell cycle distribution 202 
compared to the DMSO control (Fig. 2A). TSC24 treatment increased the population 203 
of cells with sub-G1 and post-G1 DNA content (Fig. 2B). This action of TSC24 is in 204 
contrast to the effect of the compound on the cell cycle progression in mammalian 205 
cells where the thiosemicarbazone has been reported to induce a G1-S arrest (Huang 206 
et al., 2010). However, our finding is reminiscent of the action of idarubicin, a 207 
classical topoisomerase II inhibitor, on T. rangeli where the drug has also been 208 
demonstrated to lead to DNA degradation (Jobe et al., 2012). When bloodstream 209 
forms of T. brucei were incubated with TSC24 in the presence of iron, an increase in 210 
cells in the G1 phase was observed (Fig. 1C). This result resembles the action of 211 
Dp44mT and TSC24 found for mammalian cells where the compounds induce a G1-S 212 
cell cycle arrest (Rao et al., 2009; Huang et al., 2010). 213 
To investigate whether the trypanotoxic action of TSC24 and Dp44mT was the 214 
result from a synergistic effect of their iron chelating and topoisomerase II inhibiting 215 
activity, a combination assay was carried out. Although the iron chelating properties 216 
of TSC24 and Dp44mT is known to be due to their thiosemicarbazone scaffold, the 217 
part of the molecules responsible for their topoisomerase inhibiting properties is not 218 
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known. Therefore, a combination assay was designed using two separate agents, the 219 
iron chelator deferoxamine and the topoisomerase II inhibitor epirubicin. The 220 
combination of deferoxamine with epirubicin showed an antagonistic effect with a CI 221 
of 1.49±0.25 (Fig. 3). Whereas the GI50 of deferoxamine dropped from 10.8±2.1 μM 222 
to 4.5±0.6 μM, the GI50 of epirubicin remained unchanged (108±17 nM vs 113±14 223 
nM). This result suggests that iron chelation and topoisomerase inhibition probably do 224 
not show trypanocidal synergy. 225 
 226 
3. Discussion 227 
 228 
As bloodstream forms of T. brucei contain only four iron-dependent enzymes 229 
(aconitase, alternative oxidase, ribonucleotide reductase and superoxide dismutase) 230 
and do not express any iron storage proteins, they are more prone to iron-depletion 231 
than mammalian cells (Breidbach et al. 2002). Thus, iron chelation could be an 232 
interesting approach for the development of new trypanocidal drugs. In this study, we 233 
investigated the trypanotoxic activity of newly designed thiosemicarbazones that in 234 
addition to their iron chelating properties display inhibitory activities against different 235 
enzymes. Aiming simultaneously at two biological targets with one drug may achieve 236 
greater therapeutic efficacy due to synergistic effects. 237 
All three thiosemicarbazones studied showed similar trypanotoxic activities. The 238 
addition of iron reduced the anti-trypanosomal action of TSC24 and Dp44mT but not 239 
that of 3-AP. This may be explained by the different inhibitory mechanism of the 240 
compounds. Whereas the anti-proliferate effect of Dp44mT and TSC24 have been 241 
attributed to both iron chelation and inhibition of topoisomerase IIα (Rao et al., 2009; 242 
Huang et al., 2010), that of 3-AP is due to the destruction of the tyrosyl radical of the 243 
β2 subunit of ribonucleotide reductase through the active reductant [Fe(II)-(3-AP)] 244 
(Aye et al., 2012). As the activity of 3-AP requires binding of iron, supplementation 245 
of the metal would not be expected to significantly affect the toxic action of the 246 
compound. An alternative mode of action was reported for Dp44mT involving redox 247 
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cycle of the iron-Dp44mT complex to generate reactive oxygen species (ROS) (Yuan 248 
et al., 2004). Similar to 3-AP, iron supplementation should not affect this activity of 249 
Dp44mT as the production of ROS requires the metal. However, as the addition of 250 
iron reduces the anti-trypanosomal effect of Dp44mT, this additional mode of action 251 
involving the production of ROS doesseems not seem to be responsible for the 252 
trypanotoxic activity of the compound. 253 
The cytotoxic activity of Dp44mT and TSC24 has been associated with the 254 
ability of the compounds to induce cell cycle arrest at the G1-S checkpoint (Rao et al., 255 
2009; Huang et al., 2010) which is consistent with previous reports of most iron 256 
chelators (Brodie et al., 1993; Yu et al., 2007). Our results indicate that the 257 
mechanism of action of the two thiosemicarbazones on the cell cycle in bloodstream 258 
forms of T. brucei is different from that in cancer cells. In the absence of iron, the 259 
compounds caused a reduction in the DNA content in many cells. This finding is 260 
indicative for degradation of DNA suggesting a topoisomerase II independent 261 
mechanism of trypanotoxic action for the compounds similar to that of idarubicin 262 
described previously for T. rangeli (Jobe et al., 2012). In the presence of iron the 263 
thiosemicarbazones caused an increase of bloodstream form trypanosomes in the G1 264 
phase which suggests that some of the trypanosomes had undergone cell cycle arrest 265 
at the G1-S boundary. It appears that in the absence of iron Dp44mT and TCS24 266 
display different actions towards trypanosomes than to cancer cells. However, it 267 
should be mentioned that bloodstream forms of T. brucei have a much lower iron 268 
content than mammalian cells (Schell et al., 1991). Therefore, it is possible that the 269 
thiosemicarbazones within cancer cells quickly bind iron and execute their activity 270 
only as an iron complex while in bloodstream form trypanosomes they operate mainly 271 
as iron-free compounds. This suggestion is supported by the fact that iron 272 
supplementation has a much greater abrogating effect on the trypanotoxic activity of 273 
Dp44mT and TSC24 (13-fold reduction) than on their cytotoxic activity (~6-fold 274 
reduction). That iron supplementation has only a minor effect on the cytotoxic activity 275 
of TSC24 has been previously demonstrated (Huang et al., 2010). 276 
Comment [DS1]: ‘Seems not’ is 
perfectly correct but is more archaic and 
less used today. So my correct is only a 
suggestion.  
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Although TCS24 has been demonstrated to have both iron chelating and 277 
topoisomerase inhibiting activities with both actions believed to contribute to its 278 
cytotoxicity against a range of cancer cell lines (Huang et al., 2010), it remains 279 
unclear whether both activities contribute also to the trypanotoxic action of the 280 
compound. The partial reversal of the anti-trypanosomal activity of TSC24 upon iron 281 
addition may indicate that both actions play a role and act synergistically. However, 282 
combination experiments carried out with the iron chelator, deferoxamine, and the 283 
topoisomerase II inhibitor, epirubicin, showed no synergy between iron chelating and 284 
topoisomerase inhibiting actions. As, in this test, two separate agents were used, it is 285 
possible that the two compounds interfere with each other’s activity reducing their 286 
efficacy. Another explanation for a possible difference in the interaction of iron 287 
chelating and topoisomerase II inhibiting activity of TSC24 and 288 
deferoxamine/epirubicin combination may lie in the different topoisomerase 289 
inhibition mechanism of TSC24 and epirubicin. Whereas TSC24 is a catalytic 290 
inhibitor inactivating topoisomerase II via binding to the APTase domain and 291 
blocking the ATP hydrolysis activity of the enzyme (Huang et al., 2010), epirubicin is 292 
a topoisomerase poison that intercalates between DNA base pairs and stabilises the 293 
DNA-enzyme complex (Coukell and Faulds, 1997). 294 
In summary, the three thiosemicarbazones investigated in this study all show GI50 295 
values below 300 nM for bloodstream forms of T. brucei. These values are within the 296 
range of GI50 values reported previously for other topoisomerase inhibitors for 297 
trypanosomes (Deterding et al., 2005). In addition, the MIC value of TSC24 and 298 
Dp44mT was similar to that of suramin (1 μM), one of the current drugs used to treat 299 
sleeping sickness (Merschjohann et al., 2001; Steverding et al., 2014). However, the 300 
selectivity of the thiosemicarbazones was poor. While the MIC values showed that the 301 
compounds did not kill human HL-60 cells, the GI50 values indicated unsatisfactory 302 
cytotoxicity of the agents. Nevertheless, the actual clinical selectivity of the 303 
thiosemicarbazones may be much higher. As the thiosemicarbazones have been 304 
selected for cytotoxic action against cancer cells, their anti-proliferative effect on HL-305 
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60 cells may, therefore, be an overestimate for a healthy cell response. Whether 306 
thiosemicarbazone iron chelators are interesting compounds for further anti-307 
trypanosomal drug development remains to be shown. 308 
  309 
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Table 1 
MIC and GI50 values of the thiosemicarbazones TSC24, Dp44mT and 3-AP for T. brucei bloodstream forms and human HL-60 cells. 
Compound T. brucei      HL-60     
 MIC (μM)   GI50 (μM)   MIC (μM)   GI50 (μM)  
 −Fe +Fe  −Fe +Fe  −Fe +Fe  −Fe +Fe 
TSC24 1 100  0.287±0.020 3.642±2.068  >100 >100  0.122±0.058 0.617±0.077 
Dp44mT 1 100  0.226±0.082 3.069±0.436  >100 >100  0.005±0.002 0.036±0.025 
3-AP 100 100  0.236±0.093 0.322±0.046  >100 >100  0.673±0.054 1.537±0.921 
Data are mean values± SD of three experiments. 
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Table 2 
MIC and GI50 ratios of cytotoxic to trypanotoxic activities of the thiosemicarbazones 
TSC24, Dp44mT and 3-AP. 
Compound MIC(HL-60)/MIC(T. brucei)  GI50(HL-60)/GI50(T. brucei) 
 −Fe +Fe  −Fe +Fe 
TSC24 >100 >1  0.43 0.17 
Dp44mT >100 >1  0.02 0.01 
3-AP >1 >1  2.85 4.77 
MIC and GI50 ratios were calculated from MIC and GI50 values shown in Table 1. 
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FIGURE LEGENDS 
 
Fig. 1. Structures of the iron-chelating thiosemicarbazones TSC24, Dp44mT and 3-
AP. The PubChem Compound Identifier (CID) for each compound is shown in 
parentheses. 
 
Fig. 2. Cell cycle distribution of T. brucei exposed to TSC24. Bloodstream form 
trypanosomes were treated with 50 μM iron(III) (A), 0.5 μM TSC (B) or 5 μM TSC 
plus 50 μM iron(III) (C). The dotted trace in each graph is the result of the DMSO 
control culture. After 24 h incubation, the trypanosomes were stained with propidium 
iodide and the DNA content analysed by flow cytometry. 
 
Fig. 3. Isobolographic plot for the interaction between the iron chelator deferoxamine 
and the topoisomerase II inhibitor epirubicin. Bloodstream forms of T. brucei were 
incubated with twofold serial dilutions of the drug combination (1:1) or the drugs 
alone. After 48 h of incubation, live cells were counted and GI50 values determined. 
The dotted line that connects the GI50 points for the single drug treatments (filled 
squares) is the theoretical additive line. The GI50 of the combinations is indicated by 
the open circle. Each point represents the mean ± SD of three independent 
experiments. 
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FIG. 1 
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FIG. 2 
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Fig. 3 
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